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AT A GLANCE COMMENTARY: 
Scientific Knowledge on the Subject 
Evidence from previous studies has supported the hypothesis that T cells protect 
against influenza disease and virus shedding. However, the extent of naturally pre-
existing T cell responses across the community and their protective effect against 
nasal viral shedding (which is the best measure of influenza infectiousness) in 
naturally acquired pandemic and seasonal infection has not been determined 
previously.  
What This Study Adds to the Field 
In those infected with seasonal or pandemic influenza A, commonly occurring cross 
protective T cells targeting internal proteins have a major effect on population 
immunity by protecting against symptomatic PCR-confirmed disease. Vaccines 
stimulating T cells may provide important cross-protective immunity.    
This article has an online data supplement, which is accessible from this 
issue’s table of content online at www.atsjournals.org 
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NATURAL T CELL MEDIATED PROTECTION AGAINST SEASONAL AND 
PANDEMIC INFLUENZA 
ABSTRACT 
Rationale: A high proportion of influenza infections are asymptomatic. Animal and 
human challenge studies and observational studies suggest T cells protect against 
disease among those infected, but the impact of T cell immunity at the population 
level is unknown.  
Objectives: To investigate whether naturally pre-existing T cell responses targeting 
highly conserved internal influenza proteins could provide cross-protective immunity 
against pandemic and seasonal influenza.  
Methods: We quantified influenza A(H3N2) virus specific T cells in a population 
cohort during seasonal and pandemic periods between 2006-2010. Follow-up 
included paired serology, symptom reporting and PCR investigation of symptomatic 
cases. 
Measurements and Main Results: 1414 unvaccinated individuals had baseline T 
cell measurements: (1703 participant observation sets). T cell responses to A(H3N2) 
virus nucleoprotein (NP) dominated and strongly cross-reacted with A(H1N1)pdm09 
NP (p<0.001) in participants lacking antibody to A(H1N1)pdm09. Comparison of 
paired pre- and post-season sera (1431 sets) showed 205 (14%) had evidence of 
infection based on four-fold influenza antibody titre rises.  The presence of NP 
specific T cells before exposure to virus correlated with less symptomatic, PCR-
positive influenza A (overall adjusted odds ratio 0.27 (95% Confidence Interval, 0.11-
0.68), p=0.005, during pandemic (p=0.047) and seasonal periods (p=0.049)). 
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Protection was independent of baseline antibodies. Influenza specific T cell 
responses were detected in 43% indicating a substantial population impact. 
Conclusions: Naturally occurring cross-protective T cell immunity protects against 
symptomatic PCR-confirmed disease in those with evidence of infection and helps to 
explain why many infections do not cause symptoms.  Vaccines stimulating T cells 
may provide important cross-protective immunity.     
 
 
  
 
 
 
 
 
 
 
 
Abstract word count: 249 
Keywords: Cellular Immunity, T-Lymphocytes, Cohort Studies  
T Cell Mediated Protection Against Influenza 
 
9 
 
INTRODUCTION 
Our recent research shows influenza infects around 18% of unvaccinated individuals 
each year, but up to 75% of those infections are asymptomatic.1-3 The underlying 
immunological correlates of asymptomatic infections are not well understood. 
Antibodies, specific for hemagglutinin (H) and neuraminidase (N), protect against 
repeat infection4, but these proteins are highly variable enabling the virus to cause 
annual winter epidemics.5 Sporadically, a new pandemic virus emerges, with 
introduction of genes from animal reservoirs.6 Absence of pre-existing antibody 
immunity during pandemics can cause more severe illness and high mortality rates.7 
In 2009, a new pandemic A(H1N1) virus appeared with gene segments from avian, 
porcine and human viruses.8 H1 and N1 proteins were sufficiently distant from 
previously circulating viruses to evade antibodies prevalent in the human population.8  
Most infections were asymptomatic or minimally symptomatic1 and mortality rates 
were considerably lower than feared.8,9 However, the emergence of pathogenic avian 
influenza viruses, such as the A(H7N9) subtype which has caused recent human 
deaths in China,10 remains a constant threat.  
Whilst antibodies prevent infection, T cell responses which target the highly conserved 
internal proteins of influenza A virus such as nucleoprotein (NP) and matrix (M) protein 
may prevent or modulate symptoms following influenza infection.  CD8+ T cells cannot 
prevent initial infection, but they, and to some extent CD4+ T cells, mediate viral 
clearance after infection in mice.11-15 Experimental influenza A virus infection induces 
murine CD8+ T cells responses that reduce the severity of subsequent infection with 
viruses of different H and N subtypes.11-13,16,17 Human challenge studies provided the 
first evidence that pre-existing T cells protect against seasonal influenza disease; but 
generalizing findings from artificial infections has been difficult.18,19   
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A recent study reported pre-existing T cell protection against natural pandemic 
influenza disease in healthy adults amongst 25 participants infected with influenza.20 
However, it is not clear whether such protection is important in the wider community, 
whether T cells provide protection against both pandemic and seasonal strains, and 
what the extent of protection is against PCR-positive disease. 
There is substantial interest in alternative vaccine strategies since cross-protection 
with conventional vaccines is minimal. Stimulation of T cell responses targeting highly 
conserved internal proteins of influenza A virus offers the promise of both reducing 
morbidity and spread of virus shed from the upper respiratory tract.21,22 Vaccines 
targeting the T cell response are in development.23-25 A further, suitably powered 
demonstration of the population importance of T cell mediated protection against 
seasonal and pandemic infection would help to justify future investments in trials of 
such vaccines.  This study aimed to define the role of T cell based immunity in 
protection against seasonal and pandemic influenza in the general population.  
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METHODS 
Cohort Design 
The Flu Watch Study has been described previously.1 In brief; each autumn (2006-
2009) general practices (GP) across England randomly selected individuals from GP 
lists and invited their households to participate over the coming winter.  Participants 
were asked weekly for symptoms of “cough, cold, sore throat or ‘flu-like illness” and 
completed prospective daily symptom diaries throughout any illness. The Oxford 
MultiCentre Research Ethics Committee approved this study and participants gave 
written-informed consent. 
PCR detection of virus shedding 
Participants submitted, by mail, nasal swabs on day 2 of any illness for Reverse 
transcription polymerase chain reaction (RT-PCR) identification of influenza and other 
respiratory viruses.26,27 Since qualitative real-time assays were used, we felt it was 
inappropriate to use Ct values to make quantitative inferences about viral shedding. 
Meaningful quantitative measurement would require samples to be taken in a highly 
standardised way, with close attention to time from symptom onset and rapid transfer 
to the laboratory. This was not possible due to the geographically dispersed 
community nature of this research which relied on self-sampling and postal submission 
by participants. 
Serology 
Pre- and post-season sera were batch-tested for anti-influenza virus antibody using 
haemagglutination inhibition assays (see the online data supplement). Seroconversion 
was defined as a four-fold titre rise and considered indicative of infection occurring 
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between baseline and follow up samples.  We excluded vaccinated participants 
because of the difficulty in interpreting four-fold titre rises in the context of vaccination. 
T cells 
Ex vivo T cell responses to overlapping peptides representing the whole proteome of 
influenza A(H3N2) virus, prevalent in 2006/7 and 2008/9, were measured by 
interferon- ELISpot assay28 before each influenza season (see the online data 
supplement).   
The ELISpot assay did not distinguish CD4 from CD8 T cell responses. Therefore in 
stored samples from a random subset of unvaccinated individuals taken during the 
winter wave of the pandemic (n=174), T cells were further cultured and CD4+ and 
CD8+ T cell responses were then quantified by measuring intracellular interferon-by 
flow cytometry (see the online data supplement).29 Staff conducting serological and 
virological assays were blind to T cell results and vice versa. 
Statistical Analysis 
We focused on the immunoprevalent, highly cross-reactive NP specific T cell 
responses and the dominant strain of influenza circulating in any given year. Linear 
regression models were used to investigate the relationship between log-transformed 
T cell responses and serological/symptom variables.  We used poisson regression 
models to explore the effect of NP response and other variables on rates of infection. 
Logistic regression models were built to test the primary hypothesis that pre-existing 
T cell responses to NP would protect against detectable viral shedding in individuals 
serologically infected with influenza. Robust standard errors accounted for correlation 
between repeated measurements in the same individual, and potential confounders 
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were adjusted for. Fisher’s exact test was used to assess the protective effect of 
response separately for pandemic and seasonal influenza.  Sensitivity analyses using 
the less specific respiratory illness outcome are reported in the online supplement. 
Estimates are presented with a 95% confidence interval and a p-value (p<0.05 was 
considered statistically significant). Analyses were performed in STATA 12. 
There is no accepted threshold for quantifiable ex-vivo influenza specific T cell 
responses. Therefore values of ≥20 spot forming units per million (SFU/M) peripheral 
blood mononuclear cells (PBMC) (above the 99th percentile of the negative control well 
distribution) were considered detectable if the original pooled test well result was also 
significantly higher than the pooled negative control well results (p<0.05, negative 
binomial distribution).  
 
 
RESULTS 
1414 participants met inclusion criteria, some contributing to more than one season: 
2006/7 (n=321); 2007/8 (n=404); 2008/9 (n=322); 2009/10 (n=656) giving 1703 
observation sets. Follow-up serology was available for 84% (1431/1703). Of these, 
14% (205/1431) were infected with the season’s dominant circulating influenza A 
strain (four-fold rise in specific antibody titre). Infected participants contributed 2289 
person weeks follow-up with illness status reports returned for 1877 (82%) weeks. 
Amongst those infected there were 143 illnesses reported with 112 (78%) submitting 
nasal swabs (see Table E1 in the online data supplement). 
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Baseline influenza-specific T cell responses to peptide pools spanning individual 
proteins in the majority of participants were low (Figure 1A and B) but comparable to 
previous studies.18,30 The median total A(H3N2) specific T cell response after 
subtraction of background no-peptide control responses was 83 SFU/M PBMC. NP 
was the immunodominant antigen (median ex vivo NP T cell response 15 SFU/M 
PBMC). 25% of the total T cell response was specific for NP and 19% for M (Figure 
1C summarises variation in the proportion of the total response due to each protein by 
individual). 43% (730/1703) of observations had a T cell response to NP (≥20 SFU/M 
PBMC) compared to 35% for M (Figure 1D). NP T cell responses were detectable in 
45% (65/146), 53% (302/570), 40% (319/804) and 24% (44/183) of baseline ex vivo 
assays in children aged 5-15, young adults aged 16-44, older adults aged 45-64 and 
those aged 65 and over respectively (chi-squared p<0.001).  We found strong 
evidence (p<0.001) of cross-reactivity between T cell responses to H3N2 and 
A(H1N1)pdm09 (Figure 2A and B).  Using a culture assay, to expand antigen specific 
T cells in the presence of peptide and IL-2, followed by peptide stimulated cytokine 
expression and flow cytometry, we found that the contribution of CD8+ T cells was 
higher for the internal influenza proteins compared to HA and N, and highest for NP 
(Figure 3). NP specific ELISpot responses ex vivo and cultured NP responses in vitro 
were strongly correlated (log transformed regression coefficient 0.86 (95% Confidence 
Interval (CI) 0.36-1.36) p<0.001). This correlation held for influenza specific CD8+ cells 
(1.65 (95% CI 1.02-2.28) p <0.001) but not for CD4+ cells (0.45 (95% CI -0.16-1.06) 
p=0.146) (See Figures E1A-C in the online data supplement). There was no evidence 
that NP-specific T cell responses differed at baseline between those vaccinated and 
unvaccinated in the last two years (age and baseline antibody adjusted odds ratio 
0.96, 95% CI 0.71 to 1.28, p=0.77). 
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The primary outcome was the nasal shedding of influenza virus as detected by PCR. 
The average incubation period (time between infection and symptom onset) is 48 
hours and viral shedding generally peaks another 24 hours later.18 Viral shedding is 
associated with both disease severity and infectiousness.2,31 The rate of serologically 
confirmed infections per 100 person seasons was strongly inversely associated with 
baseline homotypic antibody titre but as expected was not affected by baseline NP 
specific T cell response (Table 1).  Amongst those infected 35/205 (17.1%) shed 
detectable influenza virus from nasal swabs taken during illness (cough, cold, sore 
throat or influenza like illness) (Table 1). In univariate analysis the primary outcome 
was only associated with an NP specific T cell response and gender, with viral 
shedding lower in those with a response and in females.  In the final adjusted model 
only a pre-exposure NP specific T cell response ≥20 SFU/M PBMC was significantly 
associated with reduced odds of nasal viral shedding (adjusted odds ratio 0.27 (95% 
CI 0.11-0.68), p=0.005).  The protective effect was significant for seasonal influenza 
(9.9% (6/66) of those with a detectable NP response shed influenza virus vs 21.7% 
(20/92) of those without, Fisher’s exact test p=0.049). The protective effect was equally 
significant for pandemic influenza (0% (0/13) of those with NP response shed virus vs 
26.5% (9/34) of those without, p=0.047). Although the study is underpowered for 
further breakdown by seasonal influenza strain, the direction of effect was the same 
for both seasonal H1N1 and H3N2.  For those infected with seasonal H1N1 8/32 
(25.0%) of those without a baseline T cell response shed seasonal H1N1 virus 
compared to 1/24 (4.2%) of those with a baseline T cell response (Fisher’s exact 
p=0.063). For those infected with H3N2 12/78 (15.4%) of those without a detectable 
NP  shed H3N2 virus vs 6/57 (10.5%) of those without a detectable NP response 
(Fisher’s exact p=0.454). Amongst those who shed virus we found no evidence of a 
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positive or negative correlation between pre-exposure NP specific T cell responses 
(log transformed SFU/million PBMC) and log transformed symptom severity scores 
(correlation coefficient 0.30, 95% CI -0.19 to 0.79, p=0.225).   
In sensitivity analyses, using the less specific outcome of self-reported respiratory 
illnesses (cough, cold, sore throat or influenza like illness) in those with serological 
evidence of infection (excluding illnesses known to be due to other viruses and those 
occurring outside the period of influenza circulation), we found no significant protection 
associated with the baseline NP specific T cell response in the seasonal epidemics. 
However, in 34 participants infected with the pandemic strain who did not have a 
positive baseline NP specific T cell response, there were 33 illnesses. This contrasts 
with 4 illnesses amongst 13 participants infected with the pandemic strain who had a 
positive baseline ex vivo NP T cell response (age and baseline antibody adjusted 
Incidence Rate Ratio 0.49, 95% CI 0.25-0.96, p=0.037).  
 
 
DISCUSSION 
We show that pre-existing cross-reactive T cell responses to NP were independently 
associated with decreased odds of nasal viral shedding in those infected with seasonal 
or pandemic influenza. Whilst homotypic antibodies provide strong protection against 
infection, our work supports our primary hypothesis that, in those who become 
infected, baseline T cells provide heterotypic protection against the highly specific 
outcome of detectable viral shedding.  T cell responses at protective levels were 
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present in 43% of participants and correlated with a reduced risk of shedding virus by 
around two-thirds, indicating an important population level effect.    
This is the first large community cohort study of human T cell immunity against 
influenza. The large study size allowed assessment of both confounders and 
interactions. It covered a cross section of the population and spanned both seasonal 
and pandemic periods. Weekly follow-up minimised recall bias but was less intense 
than during human challenge studies likely leading to some under-ascertainment of 
influenza illnesses and viral shedding. PCR on self-submitted nasal swabs have been 
shown to have comparable sensitivity to samples taken by healthcare workers.32 
Sensitivity analyses using the more sensitive but less specific outcome of respiratory 
illness show similar cross-protective immunity against illness in those infected with the 
2009 pandemic strain, perhaps unsurprising given the virological dominance of 
A(H1N1)pdm09 during 2009-10.1 Because nasal swabbing was only requested from 
symptomatic individuals we are unable to determine whether T cells affected viral 
shedding in asymptomatic infection.33 We did not measure baseline innate immune 
responses, which by definition are not antigen-specific. Severe influenza involves 
hyper activation of innate immune responses in the lungs, particularly of monocytes 
and macrophages populations.34 These responses are also involved in mild disease 
involving only the upper respiratory tract, particularly in children, but investigating this 
was beyond the scope of our study.35-37  
Participants had baseline influenza specific memory T cell responses at low levels 
which is compatible with the known expansion and contraction of T cells following 
acute viral infection.18 Stringent criteria were applied to define a robust threshold (≥20 
SFU/M PBMC) for detectable ELISpot responses ex vivo. This cut-off is lower than 
that used in vaccine testing, but is statistically sound given the very low backgrounds 
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in the assays and is appropriate because of the low level of baseline T cell responses 
in the general population. The few very strong responses may have identified actively 
infected participants sampled during the early stages of the epidemic or pandemic, 
which was possible because the pre-season bleeds were not completed before the 
influenza season had started. However exclusion or inclusion of these donors in the 
sensitivity analyses did not affect conclusions.  
The main previous evidence of T cell based protection in naturally acquired influenza 
comes from a London based cohort study over the 2009/10 and 2001/11 seasons of 
the pandemic.  Healthy adults (n=342, median age=28) recruited at a 
University/Medical School were asked to report symptoms every three weeks and 
submit self-taken nasal swabs during illness. By contrast we report 1703 participant 
observation sets from 1414 general population participants across all age groups and 
including those with chronic illness followed up over periods of both pandemic and 
seasonal influenza.  We used weekly symptom reporting and self-submission of nasal 
swabs to maximise ascertainment of influenza. In the previous study the infected 
group (n=43) was identified on the basis of 4 fold antibody titre rises or positive PCR. 
The authors do not make it clear whether those who were vaccinated between 
baseline and follow up bleeds were excluded (which would be expected to cause a 4 
fold titre rise).  We exclude those in whom vaccination could have caused 4 fold titre 
rises from our definition of infection.  The previous study analyses T cell responses as 
a continuous variable whereas we categorised our T cell results into positive and 
negative responses as described above.  This was both because the highly skewed 
distribution of the responses meant it could not be readily transformed to meet 
assumptions of appropriate statistical tests and because we saw no evidence of a 
quantitative effect above this binary cut off.  Neither study found evidence of T cell 
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protection against infection.  In the previous study infected patients who reported 
multiple illnesses during follow up were excluded as it was not considered possible to 
identify which illness was caused by influenza, leaving 25 adults for study of the 
protective effect of T cells.  We did not exclude such patients as our primary outcome 
was PCR-confirmed disease which did not occur more than once during follow up and 
our secondary outcome was whether or not participants reported illness during follow 
up. Thus our main analysis focusses on 205 infected patients.  In the previous study, 
when examining total pre-existing cross-reactive total cytokine-secreting T cells to live 
pH1N1 virus in the 25 infected patients, they report higher baseline T cell results 
amongst those who reported no fever (n=12,  p=0.03), amongst those with completely 
asymptomatic infection (n=3, p=0.02) and amongst those with lower symptom scores 
(p=0.05), but no difference in those who were PCR positive (n=11).  By contrast we 
found no protective effect of total cell response to H3N2 influenza proteins against 
PCR positive disease, symptoms or symptom scores.  In the previous study, when 
examining cellular responses to highly conserved CD8 epitopes from the 
immunodominant internal PB1, NP and M1 proteins in these 25 patients, they reported 
higher baseline levels amongst those who reported no fever (n=12, p=0.02), no ILI 
(n=15, p=0.04) and those with lower symptom scores (p=0.01).  Finally, when 
examining IFN-γ+IL-2− T cells specific for conserved CD8 epitopes they found 
negative correlations with symptom scores (p=0.004) and higher baseline levels in 
those who were PCR negative (p=0.05).  By contrast we focussed analyses on the 
response to the immunodominant NP protein (where the response was shown to be 
dominated by CD8 cells). We found those with a positive response at baseline were 
less likely to shed virus (adjusted odds ratio 0.27 (95% CI: 0.11-0.68, p=0.005), during 
pandemic (p=0.047) and seasonal periods (p=0.049)), and during the pandemic were 
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less likely to report symptoms.  We found no association with total symptom scores 
(although we used lower weights for severe symptoms compared to the previous 
report). Given the different population groups and methods utilised we consider both 
studies to provide consistent evidence that baseline cross reactive CD8 T cell 
responses to conserved internal proteins do not protect against infection with influenza 
but do protect against symptoms and PCR positive disease in those infected with the 
pandemic strain.  In addition we show protection against PCR positive seasonal 
influenza.  We also show that around 43% of the population have baseline T cell 
responses associated with protection indicating a substantial role of T cells for 
protection at a population level (see Table E2 in the online data supplement for a 
summary comparison of these two studies).  
Influenza symptoms with fever appear around 48 hours after infection18 and nasal 
swabs to detect virus shedding in the nose by PCR, were taken from the second day 
of illness. Therefore the T cells had at least 72 hours to act before the swab was taken. 
This time would allow accumulation of T cells at the site of infection in the upper 
respiratory tract and some expansion. Memory T cells can respond by releasing 
interferon- and other cytokines within 6 hours of antigen contact38 and can expand up 
to 10,000-fold in ten days, approximately one division every 20 hours.39 Therefore 
even low levels of functional memory T cells in the blood of 20/million, which is 
equivalent to 105 in the whole blood volume, could provide enough T cells to migrate 
to the site of infection to clear virus quickly. The lower frequency of detectable nasal  
virus shedding in  infected participants (proven by an antibody rise) with positive 
baseline NP specific T cell responses compared to those without this response 
suggests that T cells promote more effective control of infecting virus in the upper 
respiratory tract. There was a strong correlation between ex vivo NP specific T cell 
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responses and cultured CD8+ T cell responses to NP, but no such correlation with 
cultured CD4+ T cell responses. Thus the NP specific T cell response, which was the 
most prevalent influenza protein-specific response and which showed an independent 
protective effect comprised proportionately more CD8+ T cells than CD4+ T cells. 
Therefore, as also reported by others NP specific CD8+ T cells are likely to be 
important mediators of protection.20 However, we cannot exclude some additional 
protective effect of CD4 T cells, as shown in a previous small challenge study19 just 
as that study could not exclude a role for CD8 T cells. Most likely both are involved. 
We excluded vaccinated participants from the analysis, but found no evidence that T 
cell responses at baseline were associated with recent vaccination. This is consistent 
with previous research that has shown that subunit vaccines fail to, or only weakly, 
stimulate CD8 T cell responses.12,40 At the time of the study the live attenuated 
influenza virus vaccine (LAIV) was not licensed in the UK and no volunteer had been 
given that vaccine. The relatively poor protection offered by that vaccine in adults could 
be related to pre-existing T cell immunity preventing virus take; this needs to be 
explored further in future studies.  
Previous work, including animal models11-13, 16, 41-44 and some studies in humans18-20, 
suggests a potentially important role for T cell based immunity to provide cross-
protective immunity to influenza.  However this is the first study to show a significant 
strong effect for both seasonal and pandemic influenza viral shedding that is 
independent of baseline antibodies in a broadly based population sample.  
Widespread adaptive heterotypic immunity provided by cross-reactive T cells along 
with innate immune responses could help to explain why many seasonal infections are 
asymptomatic and why this phenomenon was also common in the 2009 pandemic, 
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despite antibody based immunity being very low in the population at the outset.45  
These results suggest that vaccine induction of CD8+ and/or CD4+ T cells specific for 
NP could offer partial protection by reducing virus shedding resulting in clearance of 
infection, reduced respiratory symptoms and possibly reduced influenza transmission. 
This could be useful during the first six months of a pandemic before a conventional 
vaccine becomes available. This could also be of benefit in years when vaccine is 
poorly matched to circulating influenza strains, as happened in the 2014/15 influenza 
season.46 There have been concerns that overstimulation of T cell responses could 
increase risk of post infection immunopathology.47,48 The absence of a positive 
correlation between NP concentration and symptom severity in those who do become 
ill is therefore reassuring.  Also, the experimental virus vectored vaccines currently 
being tested are unlikely to give very high levels of T cell responses in humans once 
the initial post vaccination peak is over reducing any risk.49 Therefore this 
demonstration that quite modest levels of NP specific T cells in the blood correlate 
with protection, at least for the relatively weakly virulent viruses of recent years, is 
encouraging.  
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FIGURE LEGENDS 
Figure 1. Pre-existing ex vivo influenza specific T cell response 
The pre-season ex vivo frequency of influenza (H3N2) specific T cell responses from 
1703 baseline measurements from 1414 Flu Watch participants were quantified by 
IFN- ELISpot assay. Some participants contributed to more than one season, but no 
participant had more than one baseline measurement per season.  
A: Each column represents a different baseline sample. The height of each column 
represents the ex vivo frequency (SFU/M PBMC) of H3N2 specific T cell response; 
each colour represents the T cell responses targeted at each of H3N2 viral antigens 
as indicated below the bar chart. 
B: For the same samples as in Figure 1A the ex vivo NP specific T cell responses (y 
axis) are plotted on a log10 scale and ordered on the x axis by the strength of the 
response.  
C: For the total ex vivo T cell responses in the whole study, the proportional 
contribution of each H3N2 viral antigen specificity is shown, indicating for instance 
that NP specific T cells constitute 25% of the whole response. 
D: Percentage of Flu Watch baseline samples that had ex vivo detectable memory T 
cell responses (for each influenza protein response we subtracted the negative 
control well result from the test well result and accepted values of ≥20 SFU/M PBMC 
as reactors if the original result was also significantly higher than that of the negative 
control wells (p<0.05 based on the negative binomial distribution).  
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Figure 2. Pre-existing influenza NP and M specific T cell cross-react to 
pandemic H1N1 2009 
The frequencies of T cell responses to pandemic H1N1 2009 NP and M peptides 
were quantified ex vivo from Flu Watch participants (N=222) who had no detectable 
antibody against pandemic H1N1 2009 HA at baseline. Each dot represents one Flu 
Watch participant. Panel A shows the log10 transformed ex vivo frequency of H3N2 
NP specific T cell response shown on the X axis and the log10 transformed ex vivo 
frequency of the T cells targeted at pandemic H1N1 2009 NP showing on Y axis. 
The NP T cell responses were quantified by IFN- ELISpot assay and backgrounds 
were subtracted in the data presented in this figure.  Panel B shows the equivalent 
for M responses. 
 
Figure 3. CD4 and CD8 phenotype of pre-existing influenza specific T cells 
The pre-season influenza (H3N2) specific T cell responses from 174 randomly 
selected Flu Watch participants were expanded by culture with peptide and IL-2 and 
the frequency of CD4+ and CD8+ influenza specific T cells were measured by 
intracellular interferon-staining (Y axis).The height of each column indicates the 
percentage of all influenza specific T cells (CD3+IFN-+) responding to H3N2 virus 
peptides representing each protein. The grey and red colours indicate the relative 
CD4+ and CD8+ T cell responses.
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Table 1 – Cohort characteristics and analysis of risk factors for infection and PCR-confirmed symptomatic illness in those infected. 
 Number with 
paired sera 
(person 
seasons)  
# infections 
(# per 100 
person 
seasons)* 
Unadjusted 
Incidence rate 
ratio (IRR-95% CI), 
p 
Adjusted IRR 
(95% CI), p 
# (%) of 
infections with 
PCR-positive 
influenza A*  
Unadjusted OR 
(95% CI), p 
Adjusted OR (95% 
CI), p 
NP SFU/M PBMC † 
NP < 20  869 (762) 126 (16) 1  29 (23%) 1 1 
NP ≥20  630 (562) 79 (14) 0.94 (0.70-1.25), 
0.659      
 6 (8%) 0.26 (0.10-0.64), 
0.003 
0.27 (0.11-0.68), 
0.005 
Year 
2006 294 (289) 51 (18)  1 6 (12%) 1  
2007 351 (339) 40 (12) 0.63 (0.43-0.94), 
0.024  
0.65 (0.44-0.95), 
0.03 
8 (20%) 1.5 (0.43-5.2), 0.52  
2008 285 (221) 67 (30) 1.35 (0.97-1,88), 
0.073 
1.45 (1.05-1.98), 
0.023  
12 (18%) 1.0 (0.31-3.3), 0.97  
2009 569 (475) 47 (9.9) 0.46 (0.34-0.67), 
<0.001 
0.44 (0.30-0.64), 
<0.001  
9 (19%) 1.3 (0.39-4.2), 0.69  
Gender 
Male 692 (612) 85 (14) 0.86 (0.65-1.14), 
0.303 
 19 (22%) 2.3 (1.0-6.1), 0.04 1.9 (0.91-4.1), 0.09 
Female 807 (712) 120 (17) 1  16 (13%)   
Age group 
5-15 105 (94) 25 (27) 1.76 (1.16-2.68), 
0.008    
2.56 (1.68-3.88), 
<0.001  
2 (8%) 1  
16-45 499 (440) 77 (18) 1 1 14 (19%) 2.5 (0.58-11), 0.22  
45-64 734 (651) 89 (14) 0.77 (0.57-1.05), 
0.107 
0.74 (0.054-1.00), 
0.05 
19 (21%) 2.9 (0.65-13), 0.16  
65+ 161 (139) 14 (10) 0.50 (0.28-0.91), 
0.022 
0.70 (0.37-1.29), 
0.253  
0 (0%)) n/a  
Baseline titre 
<16 1170 (1033) 186 (18) 1 1 34 (18%) 1  
16-32 206 (183) 18 (9.8) 0.58 (0.35-0.96), 
0.034  
0.42 (0.25-0.70), 
0.001 
1 (6%) 0.29 (0.04-2.0), 0.22  
64-128 89 (78) 1 (1.3) 0.06 (0.01-0.43), 
0.005 
0.04 (0.01-0.30), 
0.002  
0 n/a  
>128 34 (29) 0 (0.0) n/a n/a n/a n/a  
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*Refers to dominant influenza strain: H3N2 in 2006/7 and 2008/9; seasonal H1N1 in 
2007/8 and A(H1N1)pdm09 in 2009/10. Each year one strain of influenza A 
dominated: In 2006/7 there were 6 PCR-positive cases of H3N2; in 2007/8 there 
were 9 PCR-positive cases of seasonal H1N1 and one of H3N2; in 2008/9 there 
were 16 H3N2 and 2 seasonal H1N1 and in 2009/10 there were 12 PCR-positive 
cases of A(H1N1)pdm09. PCR and serology results refer to the dominant influenza 
strain circulating each year. 
†Nucleoprotein spot forming units per million peripheral blood mononuclear cells.  
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FIGURE LEGENDS 
Figure 1A 
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Figure 2B 
 
Figure 3 
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